Linagliptin
- TRADE NAMES: Glyxambi (Boehringer Ingelheim); Tradjenta (Boehringer Ingelheim)
- INDICATIONS: Type II diabetes mellitus
- CLASS: Antidiabetic, Dipeptidyl peptidase-4 (DPP-4) (gliptin) inhibitor
- HALF-LIFE: 12 hours
Linagliptin should not be used in patients with Type I diabetes or for the treatment
of diabetic ketoacidosis, and has not been studied in combination with insulin.
Glyxambi is linagliptin and empagliflozin.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tabs (above) to see reviews of linagliptin in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric